Dihydrofolate reductase (DHFR) catalyzes the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate and is essential for the synthesis of thymidylate, purines and several amino acids. Inhibition of the enzyme's activity leads to arrest of DNA synthesis and cell death. The enzyme has been studied extensively as a drug target for bacterial, protozoal and fungal infections, and also for neoplastic and autoimmune diseases. Here, we report the crystal structure of dihydrofolate reductase from Mycobacterium tuberculosis, a human pathogen responsible for the death of millions of human beings per year. Three crystal structures of ternary complexes of M. tuberculosis DHFR with NADP and different inhibitors have been determined, as well as the binary complex with NADP, with resolutions ranging from 1.7 to 2.0 A Ê . The three DHFR inhibitors are the anticancer drug methotrexate, the antimicrobial trimethoprim and Br-WR99210, an analogue of the antimalarial agent WR99210. Structural comparison of these complexes with human dihydrofolate reductase indicates that the overall protein folds are similar, despite only 26 % sequence identity, but that the environments of both NADP and of the inhibitors contain interesting differences between the enzymes from host and pathogen. Speci®cally, residues Ala101 and Leu102 near the N6 of NADP are distinctly more hydrophobic in the M. tuberculosis than in the human enzyme. Another striking difference occurs in a region near atoms N1 and N8 of methotrexate, which is also near atom N1 of trimethoprim, and near the N1 and two methyl groups of Br-WR99210. A glycerol molecule binds here in a pocket of the M. tuberculosis DHFR:MTX complex, while this pocket is essentially ®lled with hydrophobic side-chains in the human enzyme. These differences between the enzymes from pathogen and host provide opportunities for designing new selective inhibitors of M. tuberculosis DHFR.
Introduction
Mycobacterium tuberculosis, a human pathogen causing tuberculosis (TB), is responsible for the death of millions of people every year and continues to claim more lives than any other single infectious agent (Nakajima, 1993; Dolin et al., 1994; Snider et al., 1994; Rouhi, 1999) . Its pathogenicity arises from strategies it has developed to survive in host cells, including the ability to colonize macrophages, and to remain quiescent and then become active decades later. M. tuberculosis also has an unusual cell wall containing mycolipids with fatty acid chain lengths of sixty and more carbon atoms (Lee et al., 1996; Kolattukudy et al., 1997) . About one-third of the world population is infected with M. tuberculosis, 10 % of which will develop the disease at some point in their lives (Nunn & Kochi, 1993) . The current treatment of active TB is basically a four-drug regimen comprising isoniazid, rifampin, pyrazinamide and ethambutol for a period of at least six months (Bloom & Murray, 1992; Snider & Roper, 1992; Bass et al., 1994) . The failure of patients to complete the therapy has led to the emergence of multi-drugresistant (MDR) tuberculosis. The growing number of cases of MDR tuberculosis has become such a public health threat that the WHO has declared TB a global public health emergency (Nakajima, 1993) . Greater efforts are needed in investigating the molecular basis of pathogenicity and in developing high ef®cacy drugs for key targets in M. tuberculosis. The present study was undertaken to investigate the opportunities which the enzyme dihydrofolate reductase from M. tuberculosis offers for the development of new drugs. Studying M. tuberculosis dihydrofolate reductase (DHFR) in order to increase the ability to treat tuberculosis patients is the more relevant, since DHFR inhibitors have been shown to be of use in Cote d'Ivoire in the treatment of patients infected both by HIV and M. tuberculosis (Wiktor et al., 1999) .
Dihydrofolate reductase (DHFR, EC 1.5.1.3) is essential for folate metabolism in both eukaryotic and prokaryotic cells (Blakley, 1984 (Blakley, , 1995 Kuyper et al., 1996a,b) . The enzyme catalyzes the NADPHdependent reduction of dihydrofolate to tetrahydrofolate which is involved in a variety of biochemical functions involving single-carbon transfers. The reduced form of folate is a precursor of cofactors necessary for the synthesis of thymidylate, purine nucleotides, methionine, serine and glycine required for DNA, RNA and protein synthesis. Because rapidly dividing cells have a great demand for DNA and protein synthesis, inhibition of this enzyme by methotrexate has been exploited in cancer chemotherapy (Schweitzer et al., 1990) . Methotrexate is also used as an anti-in¯ammatory and immunosuppressive agent. In addition, selective DHFR inhibitors are playing an important role in the treatment of bacterial, protozoal and fungal infections (Schweitzer et al., 1990; Roth & Stammers, 1992; Zuccotto et al., 1998) . The clinically useful drugs have been trimethoprim (TMP) and pyrimethamine (PYR). Both TMP and PYR are potent inhibitors of bacterial and protozoal DHFRs, respectively, but are only weak inhibitors of mammalian DHFRs. Triazine WR99210 is an active inhibitor of malarial DHFR (Hekmat-Nejad & Rathod, 1997) . Because of its side effects it has been used only as an experimental drug (Can®eld et al., 1993; Fidock & Wellems, 1997; Yeo et al., 1997) .
The clinical and metabolic importance of DHFR has made it a long-standing target for enzymological studies. A wealth of biochemical and biophysical studies of DHFR from various species, including human DHFR, has provided profound insight into the catalytic mechanism and the mode of action of inhibitors (Blakley, 1995; Miller & Benkovic, 1998; Suling et al., 1998) . A sequence alignment of human and M. tuberculosis DHFRs indicates only $26 % sequence identity and, hence, there were, at the onset of this study, likely prospects for observing signi®cant differences in crucial regions of mycobacterial and host enzymes. Here, we report four high-resolution structures of DHFR from M. tuberculosis in binary and ternary complexes with its cofactor NADP and the inhibitors MTX, TMP and Br-WR99210, a derivative of WR99210 in which three chlorine atoms on the phenyl ring are replaced by one bromine atom (Figure 1 ). Structural comparison of human and tuberculosis DHFRs reveals key differences in the active sites leading to quite speci®c suggestions for design of new selective inhibitors of M. tuberculosis DHFR.
Results
The four Mtb-DHFR structures
Quality of the structures
The re®ned 1.7 A Ê structure of M. tuberculosis DHFR in complex with NADP and MTX appeared to have good geometry, a ®nal R-factor of 0.18 and an R free of 0.24 (Table 1 ). The protein structure was evaluated by the program PROCHECK (Morris et al., 1992; Laskowski et al., 1993) for the sterochemical quality. The Ramachandran plot shows that 91 % of the non-glycine and non-proline residues are in the most favored region and 9 % in the additional allowed regions (Ramachandran et al., 1966) . A SIGMAA plot (Read, 1986) indicates an overall error in atomic coordinates of 0.18 A Ê . The average B-factors are 25.7 A Ê 2 for main-chain atoms, 29.7 A Ê 2 for the side-chains and 23.7 A Ê 2 for NADP. The statistics for the three other complexes solved are very similar ( Table 1 ), indicating that a set of four good quality structures of M. tuberculosis DHFR had been obtained.
Structures of the four Mtb-DHFR complexes
Despite an overall sequence identity of as little as 20 % among DHFRs from different species (R.L. & W.G.J.H., unpublished results), all the DHFR structures exhibit the same general fold that is dominated by a central b-sheet with four¯anking a-helices (Matthews et al., 1977) . The central bsheet of Mtb-DHFR consists of seven parallel strands and a single C-terminal antiparallel strand (Figure 2(a) ). The b-sheet has a left-handed twist of about 130
. The secondary structure elements, loops and turns of DHFR from M. tuberculosis are indicated in Figure 2 (a) and (b). The structures of the four Mtb-DHFR complexes are essentially identical with the RMS differences of the main-chain atoms among these structures being about 0.3 A Ê . The largest differences, up to 1.1 A Ê , occur in the regions of loop L1, helix aB and turn T1 (18-38), helix aC H (48-58), loop L2 (68-75), a-E and loop T5 (80-90), and, bG and bH (130-154) (not shown). Among these regions, residues 18-38, 48-58, 142-154 are located close to the folate binding site, while residues 68-75 and 80-90 are close to the adenosyl group of NADP. The RMS differences of the B-factors for main-chain atoms are about 10 A Ê 2 between the binary and ternary complexes, and about 5 A Ê 2 among the ternary complexes. The largest differences in B-factors (about 17 A Ê 2 ) occur in the same regions of L1 and a-B where the biggest positional shifts are observed (not shown). Evidently the presence or absence of a ligand in the folate binding site has little effect on the overall structure of M. tuberculosis DHFR, once NADP is bound.
NADP binding to M. tuberculosis DHFR
In the holoenzyme, the coenzyme is bound in an extended conformation by the C-terminal part of NADP is a ball-and-stick model with its molecular surface being transparent. Color code for atoms: carbon in gray, oxygen in red, nitrogen in blue, and dark green for phosphorous. The nomenclature of secondary elements is the same as the b-sheet, with the nicotinamide ring inserted into a cleft formed by strands b-A and b-F. NADP interacts extensively with the protein (Figure 3(a) ). The cofactor buries upon binding to the protein $433 A Ê 2 solvent accessible surface, which is about 78 % of its total surface. The pyrophosphate moiety of NADP is interacting favorably with helix dipoles (Hol et al., 1978; Hol, 1985) by binding near to the amino ends of helices a-C and a-E. The pyrophosphate also forms a salt bridge with Arg45, whose side-chain is stabilized by interacting with Gln98. The adenine ring contacts the protein through hydrophobic interactions involving two residues, Leu65 and Leu102 on one side, and through stacking interactions with the side-chain of Arg67 in the other side. In addition, the adenine ring contacts several other residues, including Ser66, Gly80 and Gln98. While the adenosyl ribose loosely interacts with protein, its O2
H -phosphate interacts strongly with Mtb-DHFR through ®ve H-bonds involving the side-chains of Ser66, Gln68, Arg44 and the main-chain of Arg67 (Figure 3(a) ). The nicotinamide ribose only contacts protein residues in loop L1, while the nicotinamide ring interacts with residues from strands b-A, b-E, b-I and loop L1. Its amide group forms three H-bonds with main-chain atoms of Ala7 and Ile14. There are two hydrophobic residues, Ile14 and Ile20, approaching the nicotinamide ring from opposite sides.
In the three ternary complexes, each containing NADP plus an inhibitor, the conformation of the cofactor is essentially identical with that of the binary complex. Also, the interactions of NADP with protein residues are very similar. However, due to extra Van der Waals contacts with the heteroaromatic rings of the inhibitors, the buried solvent-accessible surface area of the cofactor is increased from 433 A Ê 2 in the binary complex to 471 A Ê 2 in the MTX-bound complex. This is 84 % of its total solvent accessible surface. In the TMP and Br-WR99210 ternary complexes the buried surface areas of NADP are 475 A Ê 2 and 465 A Ê 2 , respectively.
Inhibitor binding in the Mtb-DHFR ternary complexes
The conformation and binding mode of the inhibitors MTX, TMP and Br-WR99210 in three ternary complexes were clearly revealed by the electron density maps (Figure 4 
MTX binding
MTX is bound to M. tuberculosis-DHFR via contacts with strands b-A, b-E and two helices, aB and aC. The buried solvent accessible surface area is 326 A Ê 2 , about 83 % of its molecular surface area. The 2,4-aminopterin ring of MTX is situated into a 15 A Ê deep, mainly hydrophobic pocket and interacts strongly with the protein through four hydrogen bonds (Figures 3(b) and 4(a)). Asp27 from helix a-B forms two H-bonds with N1 and the 2-amino group. The latter moiety also forms a Hbond with a well ordered and conserved water molecule. The negatively charged Asp27 is highly conserved and critical for catalysis (Howell et al., 1986) . Ile5 of strand b-A and Ile94 in the carboxylterminal part of b-E form each a H-bond between their main-chain carbonyl oxygen atom and the 4-amino group of the inhibitor. In addition, the hydroxyl of Tyr100 in helix aF is within 3.2 A Ê of the 4-amino group of the MTX although the angle is not favorable for an H-bond. This arrangement of hydrogen bonds around the aminopterin ring is highly conserved among the known DHFR structures from various species. In addition to the hydrogen bonding interactions, there are many Van der Waals contacts between inhibitor and protein. On the side facing the nicotinamide ring of NADP, the aminopterin is in contact with Trp6, Ala7 and Ile20. The other side of the aminopterin ring interacts with Phe31, Ile5, Ile94, and Gln28 (Figure 4(a) ).
The p-aminobenzoyl ring of MTX is in contact with six residues, Ile50, Pro51, Ile54, Ile57, Gln28 and Phe31, which provide a hydrophobic environment for the phenyl group. The glutamate motif of the inhibitor lies on the protein surface with its side-chain atoms loosely interacting with three residues Gln28, Ala29 and Arg32 of helix a-B, while strong salt bridge interactions are observed between its a-carboxyl group and two positively charged residues, Arg32 and Arg60.
There is a glycerol molecule (hereafter called`g lycerol A'') bound close to the N8 position of MTX (Figure 4(a) ). The glycerol is bound to the protein through three H-bonds between all hydroxyl groups and residues Asp27, Gln28 and Leu24 (Figure 4(a) ). The glycerol carbon atoms are de®ned in E. coli DHFR (Matthews et al., 1977) . (b) Structure-based sequence alignment of M. tuberculosis DHFR and human DHFR made using SHOWCASE. Helices are represented by cylinders, and b-strands by arrows. Structurally equivalent residues are indicated by short vertical gray lines between the two sequences. The residues in the blue boxes are involved in NADPH and inhibitor binding. Regions R1 to R4 in the human sequence are insertions in human DHFR compared to Mtb-DHFR. in hydrophobic contact with the side-chain of Leu20. This glycerol molecule can be seen weakly in the electron density map of the ternary Br-WR99210 complex (Figure 4(c) ), but in the TMPbound complex glycerol A is absent, however (Figure 4(b) ). This might be due to the fact that in this complex the side-chain of Gln28 is disordered, which in its turn might possibly be related to the fact that the trimethoxy-substituted phenyl of TMP is in a quite different position than the phenyls of MTX and BrWR99210.
TMP binding
TMP binds at the active site of Mtb-DHFR with its pyrimidine ring being held in the interior of a deep cleft through hydrogen bond and Van der Waals interactions. The trimethoxy-benzyl sidechain extends out toward the entrance of the binding pocket, making Van der Waals contacts with residues from a-B and the carboxyl terminal end of a-C. Four residues located in the interior of the active site are involved in H-bond interactions with the pyrimidine ring (Figure 3(c) ), while the ring is in Van der Waals contact with Phe31, Ile5, Ala6, Ala7 and Ile94. The trimethoxybenzyl group of TMP interacts via Van der Waals contacts with protein residues Ile20, Phe31, and Leu50 near the entrance of the active site, and the inhibitor also contacts NADP and a glycerol molecule (glycerol B). This glycerol is located in the position occupied by the a-carboxyl group of MTX in the MTXcontaining complex.
TMP has two principal degrees of conformational freedom (y1 and y2) (Figure 1(c) ). In addition, the three methoxy groups can adopt in-plane and (Wallace et al., 1995) . Only distances below 3.4 A Ê are indicated for H-bonds (thick green dashed lines) and below 3.9 A Ê for hydrophobic interactions (thin black dashed lines). Carbon to nitrogen contacts are not depicted.
out-of-plane conformations with torsion angles designated t1, t2 and t3. The values of y1 and y2 in the TMP-containing ternary complex of Mtb-DHFR are 0 and À108 , respectively, resulting in a conformation that positions the two aromatic rings of the inhibitors nearly perpendicular to each other. The methoxy group in the para position is perpendicular to the benzene ring of TMP (t2 87 ) and the two meta methoxy groups are coplanar with the ring (t1 À 4 and t3 163 ).
Br-WR99210 binding
The Br-WR99210:NADP:DHFR complex reveals for the ®rst time the conformation of a close relative of the potential antimalarial drug WR99210 bound to any dihydrofolate reductase. While maintaining the two amino groups positioned to form four hydrogen bonds with protein residues Ile5, Asp27, Ile94 and Tyr100, the pyrimidine ring adopts a pseudo chair conformation with the C6 Figure 4 (legend opposite) moving upward out of the plane of the ring. On the other side of the chair, ®ve atoms, C2, N3, C4, and two nitrogen atoms of the amino groups are in the same plane which bends down about 20 from the triazine ring plane (de®ned by N1, C2, C4 and N5) of a fully conjugated conformation. The 4-bromo phenyl ring is adopting a similar orientation and occupying a similar position to that of the phenyl ring of MTX in the MTX-containing ternary complex (Figure 4(d) ). A 1,3-dioxypropyl group connects the two ring systems of Br-WR99210. There are six degrees of conformational freedom designated by torsion angles w1 to w6 (Figure 1(d) ). The observed values of these torsion angles are w1 131 , w2 À 165 , w3 70 , w4 41 , w5 158 , and w6 27 . The density for the p-bromo phenyl ring is not symmetric and the average B-factor is about 60 A Ê 2 , while the density representing the bromine atom is well de®ned (Figure 4(c) ), indicating a rotational mobility around the O11-C1 H bond. In addition to the H-bond interactions between the two amino groups and residues Ile5, Asp27 and Ile94 observed for all three inhibitors, the axial methyl group on C1 (CM2) of Br-WR99210 interacts with Ala7, Ile20, and the amide of the nicotinamide of NADP(H), while the equatorial methyl group (CM1) interacts with Glu28. The 4-bromo phenyl group contacts several hydrophobic residues in a similar way as observed for MTX, and its bromide group points towards the NE of Lys53 which is at a distance of about 4 A Ê . The 1,3-dioxypropyl linking group is engaged in hydrophobic interactions with Phe31, Thr46 and Leu50 (Figure 3(d) ).
In the NADP binary complex, the structure of the active site is essentially the same as in the ternary complexes, except that two glycerol molecules and three water molecules are observed in the position where inhibitors bind in the ternary complexes. The three inhibitors of the ternary complexes adopt quite similar conformations, with four highly conserved H-bond interactions to the common diaminodiazine motif, and each occupy roughly the same space, with, however, distinct differences in the precise positions of the ring systems incorporated into these inhibitors (Figure 4(d) ).
Overall structural comparison of Mtb-DHFR and human DHFR
Mtb-DHFR contains 159 amino acid residues compared with 187 for the human protein. A superposition of the enzymes from pathogen and host ( Figure 5) shows that the general fold of M. tuberculosis DHFR is essentially the same as that of the human protein, even though the human enzyme is signi®cantly larger (Figures 2(b) , 5 and 6). The RMS deviation for the 135 equivalent C a atoms, which is 85 % of Mtb-DHFR and 73 % of human DHFR, is about 1.0 A Ê with a sequence identity of 26 %. The major structural differences occur in exterior regions labeled R1 to R4 in Figures 2(b) and 5. The short turn T2 in M. tuberculosis DHFR corresponds to loop R1 (40-47) in the human reductase. The helix a-E in Mtb-DHFR is about half the length of the equivalent helix in human DHFR and the region following a-E is quite different in the two enzymes. The turn T5 in the mycobacterial enzyme is replaced by the longer loop R3 (126-131) in human DHFR. The strand b-G in Mtb-DHFR is interrupted with one residue (Glu141) bulging out, whereas the equivalent b-strand in human DHFR shows signi®cant disruption of this strand with extension of a loop consisting of ten residues (region R4, Figures 2(b) and 5). All these structural differences occur in the N-terminal side of the b-sheet away from the active site which is located at the C-terminal side of the sheet.
Most structural features at the C-terminal end of the b-sheet are similar in the proteins from pathogen and host. The major difference in the vicinity of the active site is found in loop L3 which is extended by three residues in Mtb-DHFR compared to the human enzyme (Figures 2 and 5 ). This extension of loop L3 abolishes the interactions between this loop and loop L1 as observed in human DHFR (Sawaya & Kraut, 1997; Miller & Benkovic, 1998) . The conformation of loop L1, corresponding to the``Met 20 loop'' in the E. coli enzyme, affects the accessibility of the active site, a factor to be considered in inhibitor design (Sawaya & Kraut, 1997; Miller & Benkovic, 1998) .
Structural differences in the active site of DHFR between the M. tuberculosis and human enzyme are of particular interest for the design of therapeutic compounds that would selectively bind to the M. tuberculosis protein and would not affect the normal function of the human enzyme. The sequence identity in the active and ligand binding site is signi®cantly higher, about 55 %, than the sequence identity of 17 % for the remainder of the chain but, nevertheless, some aspects of the ligand binding area of Mtb-DHFR appear to differ in a signi®cant and promising way from that in the human enzyme, as discussed below.
Comparison of the NADP binding regions in Mtb and human DHFR
In the NADP binding site, there are two interesting differences close to both N6 and N2 which could be exploited for designing selective inhibitors for Mtb-DHFR. Close to the N6 amino group of NADP in human DHFR, there are two charged residues, Lys122 and Glu123, with the carboxyl group and the amino group of these residues at a distance of about 3.4 A Ê . The equivalent residues in Mtb-DHFR are Ala101 and Leu102 in helix a-F. Both are hydrophobic residues, hence, very different in character from those in the human enzyme (Figure 6(a) and (b) ). The amino group N6 in Mtb-DHFR points in the general direction of a hydrophobic patch formed by Ala101, Leu102, and Leu82. Farther away, about 9 A Ê in Mtb-DHFR, are situated Pro105 and Tyr106 which correspond to Gln126 and His127 in human DHFR. These differences, in particular since there are hydrophobic residues in the Mtb enzyme versus hydrophilic amino acids in the human enzyme, could be used to design TB-speci®c inhibitors, for instance, by extending the N6 amino group of NADP with hydrophobic substituents.
Another structural difference in the NADP binding site between the enzymes from host and pathogen occurs close to the C2 of the adenine ring, where an extended groove occurs in Mtb-DHFR, which, in contrast, is blocked in human DHFR by Arg91 which corresponds to Gly80 in Mtb-DHFR. This difference may allow for creating NADPH and adenosine variants with substituents which bind to this relatively open groove of Mtb DHFR near the adenine C2 position, which is less accessible in the human enzyme due to the limited space between the C2 and nearby protein atoms. Hence selective binding to the M. tuberculosis enzyme by properly modi®ed NADP variant or mimics, seems within reach.
Key difference in the MTX binding regions of Mtb and human DHFR
In the ternary complex of MTX with Mtb-DHFR, the side of the aminopterin ring facing loop L1 is accessible to the solvent. A glycerol``A'' molecule is found in a depression nearby (Figures 4(a) and 7(a)). This glycerol molecule interacts with the side-chains of Trp22, Asp27 and Gln28 which form a pocket in Mtb-DHFR. In contrast, in human DHFR complexes containing folate or MTX (Davies et al., 1990; Cody et al., 1997) , this glycerol A site is well packed with three hydrophobic residue sidechains, Leu22, Pro26 and Phe31 (Figure 7(b) ), which correspond to Leu20, Arg23 and Gln28 in Mtb-DHFR. Two residues, Leu22 and Phe31, adjacent to the N8 and C7 of the inhibitor in human DHFR, restrict the accessibility of MTX to solvent, with the distance between the side-chains of Leu22 and Phe31 being about 3.8 A Ê . These two residues in the human enzyme correspond to residues Leu20 and Gln28 in Mtb-DHFR where the shortest distance between side-chain atoms is about 6.5 to 9.4 A Ê . A MTX analog with an additional group connected to N8 or C7, and incorporating features of the binding mode of the glycerol to protein, may bind to Mtb-DHFR selectively. Such a MTXderivative should be sterically and chemically hindered from forming a complex with human DHFR (Figure 7(a) and (b) ).
Since the inhibitors MTX, TMP and Br-WR99210 bind in a similar fashion to the active site (Figure 4) , the glycerol A pocket near N8 of MTX is also in the immediate neighborhood of TMP and Br-WR99210. This suggests that not only MTX but also TMP and Br-WR99210 can be extended by substituents which bind in the glycerol A pocket. These extensions to the common diaminodiazine motif which contributes the af®nity of the inhibitors could increase the selectivity of the new inhibitors over human DHFR. Clearly, such TMP and WR99210 variants would have very different chemical structures than compounds derived from MTX, increasing there- by the likelihood that novel and highly selective inhibitors of M. tuberculosis DHFR can be obtained.
Signi®cant differences were also observed on helix a-B near the glutamate moiety of MTX. Two small hydrophobic residues in Mtb-DHFR, Pro25 and Ala29, correspond to two large positively charged residues, Arg28 and Arg32 in the human enzyme, while one negatively charged residue, Glu33 in Mtb-DHFR is changed into a positively charged Arg36 in the human enzyme (Figure 7(c) and (d)). These differences are also favorable for design of selective inhibitors, since the hydrophobic area near Pro25 and Ala29 in the bacterial enzyme allows for favorable interactions with hydrophobic substituents of new inhibitors. At the same time, these hydrophobic substituents are likely to decrease signi®cantly the af®nity of the inhibitors for human DHFR. Of course, the differences observed here and elsewhere between Mtb-DHFR and human DHFR could also be exploited by entirely novel compounds not related to any known inhibitor or cofactor.
Conclusion
The four structures of Mtb-DHFR described, i.e. the binary complex with NADP and the ternary complexes with NADP plus either MTX, TMP or Br-WR99210, show clearly two major avenues for arriving at new selective inhibitors of the M. tuberculosis enzyme. One involves the exploitation of differences in side-chains in the neighborhood of the N6, and possibly of the C2, of the adenine ring of NADP. A second avenue involves the glycerol A pocket of Mtb-DHFR which is essentially absent in the human enzyme and which occurs close to the aminopterin ring of MTX (Figure 7(a) and (b) ), the aminopyrimidine ring of TMP and the aminotriazine ring of Br-WR99210. Also the g-carboxylate region of MTX is quite different in the two proteins (Figure 7(c) and (d) ). Among these differences between human and M. tuberculosis DHFR those near N6 of the adenosine and near the g-carboxylate of MTX are especially interesting since they are of the``right sign'', that is the Mtb-DHFR structure revealed pockets which are more hydrophobic in the mycobacterial enzyme than the human enzyme. This suggests that improved Mtb-DHFR inhibitors might be created by the addition of neutral and hydrophobic groups to frameworks based on known inhibitors. These hydrophobic substituents would increase af®nity and selectivity, and also be bene®cial in other ways, e.g. by enhancing the capability of the compounds to pass the mycobacterial membrane. Clearly, comparison of the structures of DHFR from host and pathogen suggests several opportunities for arriving at improved and selective inhibitors of Mtb-DHFR.
Materials and Methods

Protein purification
The cloning of the gene and the construction of the expression plasmid encoding Mtb-DHFR will be described elsewhere. Mtb-DHFR was puri®ed to homogeneity from a three liter culture of Escherichia coli harboring a recombinant plasmid using a single step af®nity chromatography on a methotrexate-sepharose column. Brie¯y, the crude extract of bacterial cells expressing Mtb-DHFR was passed through a column packed with methotrexate-sepharose CL-6B resin (1.5 cm Â 7 cm) which was pre-equilibrated with 20 mM potassium phosphate buffer A, (0.1 mM EDTA (pH 7.0), 10 mM DTT, 50 mM KCl, 20 % (v/v) glycerol). The column was washed with 250 ml of buffer A containing 1 M KCl followed by about 10 column volumes of buffer A. The DHFR was eluted with 8 mM dihydrofolate in 50 mM TES (pH 8.0), 0.1 mM EDTA, 10 mM DTT, 20 % glycerol. Active fractions were pooled, and passed through a NAP gel ®ltration column (Pharmacia) to remove dihydrofolate. Brie¯y, the NAP column (1.5 cm Â 4.9 cm), prepacked with Sephadex G-25, was equilibrated with 25 ml of buffer A. The protein sample (2.5 ml) was then loaded to the column until it completely entered the gel bed. The active DHFR was subsequently eluted by adding 4.5 ml of buffer A to the column. The enzyme was then dialyzed against buffer A and concentrated to a concentration of 40 mg/ml. The speci®c activity of the enzyme was 4.3 mmol/min per mg.
Co-crystallization of DHFR with its cofactor and inhibitors
The protein sample was diluted to various concentrations, ranging from 5 to 40 mg/ml, for crystallization experiments with the same buffer A, but containing lower concentrations of glycerol (5 %) and DTT (2 mM). Initial crystallization conditions were obtained using Crystal Screen Kit I and II from Hampton Research and Wizard I and II kits from Emerald Biostructure. Just prior to use, aliquots of DHFR were mixed with 10 mM NADPH and incubated about 15 minutes on ice. The inhibitors used in co-crystallization experiments included MTX, TMP and Br-WR99210. The K i values of MTX and TMP are 11 nM and 88 mM, respectively (W. Sirawaraporn, personal communication). The K i of Br-WR99210 is 187 nM (R. L., unpublished results). Crystallization was carried out using the hanging drop and sitting drop vapor diffusion methods in which 2ml of protein solution was added to an equal volume of reservoir solution and equilibrated against 0.5 ml of reservoir solution in a sealed chamber at 4 C. The reservoir solutions which produced crystals of binary and ternary complexes of DHFR contained 1.5-2.2 M (NH 4 ) 2 SO 4 , 0.1 M NaAc (pH 4.5), 0.1 mM NaN 3 . The protein solution contained 8 mg/ml DHFR, 5 % glycerol, 10 mM NADPH in the same buffer as used for protein sample dilution, and, for the ternary complexes, 1-5 mM of one of the three inhibitors. The molar ratios of protein to NADPH and protein to inhibitor were about 1:20 and 1:10, respectively. Crystals of MTX and TMP-containing ternary complexes grew typically to a size of about 0.2 mm Â 0.2 mm Â 0.2 mm in 7 to ®fteen days. Crystals of the binary complex were highly mosaic and contained small satellite crystals. The crystals of the Br-WR99210:NADP:DHFR ternary complex required about eight weeks to grow. Since NADPH oxidizes quite readily at low pH to NADP, we use NADP for the cofactor throughout the text.
Heavy-atom derivatization was carried out by soaking crystals with heavy-atom agents added to a synthetic mother liquor. One successful heavy-atom derivative was found by soaking crystals for 14 days in a saturated solution of ethyl mercury chloride. Another derivative, obtained by soaking in 10 mM K 2 PtCl 4 for ten days, appeared to be highly non-isomorphous to the native crystal.
Data collection and processing
Preliminary analysis of crystals was carried out using a Rigaku RU 200 rotating anode X-ray generator (CuKa; l 1.54 A Ê ) and a Raxis IIc image plate. Crystals werē ash-frozen in a liquid nitrogen stream with 20 % glycerol as cryoprotectant and a data set from a crystal of the MTX-ternary complex was collected to 2.2 A Ê resolution. This data set was processed using DENZO and scaled with SCALEPACK (Otwinowski & Minor, 1997) , which indicated that the crystal was tetragonal with space group P4 1 , cell dimensions a 60.5 A Ê , b 60.5 A Ê and c 58.8 A Ê , one DHFR molecule in the asymmetric unit and a solvent content of 60 %. The initial screening for heavy-atom derivatives was also done with the Raxis IIc.
The ®nal data sets for all complexes (see Tables 2  and 3 ), including heavy-atom derivatives and MAD data sets, were collected with synchrotron radiation using the Argonne National Laboratory Structural Biology Center beamline (19-ID) at the Advanced Photon Source (APS) and were processed with the HKL2000 package (Otwinowski & Minor, 1997) . The best data set was collected with a SBC-2 3 Â 3 mosaic CCD X-ray detector up to 1.7 A Ê resolution from a crystal of the MTX-containing ternary complex at 100 K. For the binary DHFR:NADP complex, there were some extra re¯ections due to satellite crystals. These satellite re¯ections were successfully removed in the data processing step with HKL2000. The Hg-derivative data set was collected at the APS with a wavelength in the vicinity of the L-III absorption edge of mercury. A four-wavelength MAD data set was collected for the Pt-derivative. (This data set was eventually not used for phasing but assisted in chain tracing since anomalous difference Fouriers showed peaks next to three methionines (not shown).)
Structure determination and refinement
The initial phases for the structure of Mtb-DHFR were obtained using the isomorphous differences of a Hgderivative of the MTX:NADP:Mtb-DHFR ternary complex with its anomalous differences measured at l 1.0949 A Ê . The derivative data was scaled against the native data set with SCALEIT of the CCP4 suite, indicating an isomorphous difference of 13.6 % for the data to 2.0 A Ê resolution. There was only one Hg site detectable in the difference Patterson map using programs in the CCP4 suite (Collaborative Computational Project, 1994) . The re®nement of the heavy-atom parameters and the phase calculation were carried out by the program SHARP (de La Fortelle & Bricogne, 1997) , yielding a ®gure-of-merit of 0.60 (see Table 2 ). The phases were then improved with solvent¯attening procedures using the program SOLOMON (Abrahams & Leslie, 1996) and extended to 1.7 A Ê resolution yielding a ®nal ®gure-ofmerit of 0.95. The resultant density map clearly revealed almost the whole chain of the protein molecule (Figure 8 ) and showed well de®ned densities for NADP and MTX.
The SIRAS Hg-phased and solvent¯attened electron density map was of such good quality that neither the phasing power of the MAD Pt-data set (which looked very promising) nor molecular replacement approaches (which looked initially much less promising) were further pursued.
Using the sequence alignment program CLUSTAL W (Thompson et al., 1994) , DHFR from M. tuberculosis shares about 27 % sequence identity with DHFR from E. coli as well as from L. casei, whose structures are known (Bolin et al., 1982) . Initially, models based on the latter structures were used in molecular replacement procedures with the program AMoRe (Navaza, 1994) , but this failed to provide a solution quickly. Later it appeared that a model with removal of some of the loops and one of the helices can provide the correct molecular replacement solution.
The initial model of the MTX:NADP:Mtb-DHFR complex was built with the program O (Jones et al., 1991) and included all amino acids, except for residues 69-72, and with residues Arg23, Glu33, Lys52, Asp70, Glu83, Glu133, Glu138, Glu141, Arg146 and His157 built as alanine residues. The model also contained NADP and MTX. Re®nement was carried out with the program X-PLOR (Bru È nger & Nilges, 1993) . A total of 10 % of the re¯ections were randomly selected prior to the re®ne-ment to calculate R free values for cross validation (Bru È nger, 1992) . The model was re®ned by iterative cycles of B-factor and positional re®nement followed by simulated annealing with slow cooling protocols (Bru È nger, 1988) . At this point the R-factor was 44 % and the R free 46 %. Gradually, side-chains and a total of 137 water molecules were added and a bulk solvent correction (Jiang & Bru È nger, 1994) was applied. The program DDQ (van den Akker & Hol, 1999) was used for the validation of water molecules. Four glycerol molecules were identi®ed by examining the difference (F o À F c ) and 2F o À F c electron density maps. One of these glycerols bound in a key region of the protein, as will be discussed later. Residues Pro56 and Gly96 were built in a``cis`T c Phasing power hF h i/E, where hF h i is the root mean square heavy atom structure factor and E is the residual lack of closure error.
d FOM, Figure- of-merit. Collected with synchrotron radiation using the Argonne National Laboratory Structural Biological Center beamline (19-ID) at the Advanced Photon Source (APS). All crystals are tetragonal with space group P4 1 .
a These paramenters are shown as total and last shell. b R sym AE j jI j À hIijAEI j , where I j is the intensity measurement for re¯ection j and hIi is the mean intensity for multiply recorded re¯ections.
conformation. These cis conformations are conserved in the equivalent positions of other DHFR structures, such as the E. coli, L. casei and human enzymes (Bolin et al., 1982; Cody et al., 1997) . A large pyramid-shaped feature visible in the initial electron-density map between Arg44 and Arg45, with its center about 3.8 A Ê from both positively charged guanidinium groups, was modeled as a sulfate ion. The ®nal model of the MTX:NADP:DHFR ternary complex contains 159 amino acid residues, NADP, MTX, four glycerol molecules, one sulfate and 167 water molecules.
The crystals of the binary complex containing only NADP and the two other ternary complexes, one with bound TMP and the other with Br-WR99210, were isomorphous to the crystals of the MTX-bound ternary complex (see Table 3 ). Their structures were solved using the initial model from the MTX:NADP:DHFR complex including protein atoms only. The same set of re¯ec-tions as used in the re®nement of the ®rst structure was selected for free R validation in the re®nement of these complexes. After one round of B-factor and positional re®nement, the difference electron density maps were examined in particular in and near the active sites. The ligand molecules showed up with well-de®ned densities at 2.5 to 3.0 sigma levels. Each of the models was re®ned with similar procedures as the MTX-containing ternary complex, using simulated annealing slow cooling protocols with the initial temperature set to 5000 K to decrease bias from the initial model phases. Solvent molecules were placed on the basis of peak heights in difference electron densities, hydrogen bond opportunities with neighboring atoms and well-behaved B-factors. The com- Figure 8 . Stereoview of the electron density maps of the central b-sheet in MTX-bound ternary complex. The ®nal re®ned model is shown in ball-and-stick representation. (a) Initial SIRAS map with phases calculated from a single Hg-derivative at 2.0 A Ê resolution, contoured at 1.5s. (b) Solvent-¯attened map with phases extended to 1.7 A Ê resolution using SOLOMON (Abrahams & Leslie, 1996) , contoured at 1.5 s. (c) Final 2 F o À F c density map, contoured at 1.5 s.
plexes contained three to four glycerol molecules. The ®nal R-and R free values for these complexes range between 0.18 and 0.24, respectively. Further re®nement statistics are provided in Table 3 . Solvent accessible surfaces were calculated with GRASP (Nicholls et al., 1991) . Figures were prepared with Molscript (Kraulis, 1991) and Raster3D (Merritt & Murphy, 1994; Merritt & Bacon, 1997) .
Coordinates
The coordinates have been deposited in the Protein Data Bank (PDB code: 1df7, 1dg5, 1dg7, 1dg8) .
